Engineering a Therapeutic Lectin by Uncoupling Mitogenicity from Antiviral Activity.
Swanson, M.D., Boudreaux, D.M., Salmon, L., Chugh, J., Winter, H.C., Meagher, J.L., Andre, S., Murphy, P.V., Oscarson, S., Roy, R., King, S., Kaplan, M.H., Goldstein, I.J., Tarbet, E.B., Hurst, B.L., Smee, D.F., de la Fuente, C., Hoffmann, H.H., Xue, Y., Rice, C.M., Schols, D., Garcia, J.V., Stuckey, J.A., Gabius, H.J., Al-Hashimi, H.M., Markovitz, D.M.(2015) Cell 163: 746-758
- PubMed: 26496612 
- DOI: https://doi.org/10.1016/j.cell.2015.09.056
- Primary Citation of Related Structures:  
4PIF, 4PIK, 4PIT, 4PIU - PubMed Abstract: 
A key effector route of the Sugar Code involves lectins that exert crucial regulatory controls by targeting distinct cellular glycans. We demonstrate that a single amino-acid substitution in a banana lectin, replacing histidine 84 with a threonine, significantly reduces its mitogenicity, while preserving its broad-spectrum antiviral potency ...